European Commission approves first drug for prurigo nodularis
tricked®the first and only targeted medicine for prurigo nodularis has been approved by the EC for adults with moderate to severe disease. The European Commission (EC) has extended the marketing authorization for Dupixent® (dupilumab) in the European Union (EU), to treat adults with moderate to severe nodular prurigo (PN) who are candidates for systemic therapy, …
European Commission approves first drug for prurigo nodularis Read More »